Compare ING Groep NV (ING) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ING Groep NV vs Spyre Therapeutics Inc. Common Stock — how do they compare? ING Groep NV trades at $33.08 (market cap $95.72B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B). The key difference: ING Groep NV is far larger — about 13× Spyre Therapeutics Inc. Common Stock's market cap, and ING Groep NV pays a 3.95% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold ING Groep NV for 94 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| ING | SYRE | |
|---|---|---|
Market Cap | $95.72B | $7.35B |
Volume | 2,335,394 | 1,624,631 |
Sector | Financials | Health |
52-Week High | $37.27 | $108.92 |
52-Week Low | $23.66 | $22.18 |
Typical Hold Time | 94 Days | 0 Days |
Enterprise Value | $235.88B | $6.35B |
Dividend Yield | 3.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ING trades at $33.63, up 0.72% today, with a bearish technical signal but strong fundamentals including a 28.34% net income margin and consistent earnings beats. Recent news highlights management's raised ROE target above 16% for 2027, driven by revenue growth and AI initiatives. Cash flow trends show volatile net outflows, with 2025 net cash flow at -$14.92 billion.
The outlook is mixed: analyst consensus is bullish with 65% buy ratings, but technical indicators and cash flow volatility pose risks. Upside potential hinges on execution of growth strategies and cost discipline, while regulatory scrutiny and macroeconomic pressures remain key watchpoints for investors.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
